Look out, Sanofi. Pfizer's Clostridium difficile candidate has just nabbed an FDA fast-track designation that should help it pick up some ground in the race to bring the first vaccine for the disease to market.
BOSTON-- Sanofi's Phase II trial results for its Clostridium difficile vaccine are proof that the French drug giant is leading the race for preventive therapies for the deadly bacterial infection.
With Sanofi having already begun enrollment for its 15,000-person Phase III trial, the French company has a clear lead in the race to develop a Clostridium difficile vaccine, but a growing pack is in pursuit. The latest to give chase is a group of European scientists with a new angle--they are developing an oral vaccine.
Sanofi Pasteur is entering an important period for its vaccine business. The success of its big bet on a dengue fever vaccine hangs on upcoming late phase data. And its clostridium difficile jab has just entered Phase III, too.
Oral vaccines prove an alluring alternative to painful shots, and scientists at Royal Holloway, University of London, are pioneering a new method of oral vaccination using probiotic spores--"good bacteria." The method could help boost immunity to tuberculosis and influenza, as well as prevent C. difficile.
Cubist Pharmaceuticals isn't giving up on its drug against diarrhea caused by C. difficile. After saying in June it wasn't sure whether to continue development of the drug, the Lexington, MA-based
German researchers have synthesized a carbohydrate on the surface of an extremely virulent strain of Clostridium difficile, a potentially deadly hospital-acquired infection, that could lead to a
As we put this edition of FierceBiotech to bed, there was still no word from the FDA on potential approval of Optimer Pharmaceuticals' antibiotic fidaxomicin (Dificid). The PDUFA date of May 30 falls
Sanofi Pasteur has launched an ambitious mid-stage clinical trial for an experimental new vaccine that will attempt to thwart the rising risk of hospital-acquired Clostridium difficile infection.
Medarex and Massachusetts Biologic Laboratory will share an upfront payment of $60 million and up to $165 million in milestones from Merck, which is licensing an antibody they discovered for C.